BUCCHIERI, Fabio

CAPPELLO, Francesco

RAPPA, Francesca

ZUMMO, Giovanni

Archivio istituzionale della ricerca - Università di Palermo

For personal use. Only reproduce with permission from The Lancet.THE LANCET Oncology Vol 4  August 2003    http://oncology.thelancet.com 497ReviewMetastatic bladder cancereducational book. Alexandria: American Society for ClinicalOncology, 2001: 226–44.49 Hussain M, Smith DC, Al-Sukhun S, et al. Preliminary results ofHER-2/neu screening and treatment with trastuzumab (Herceptin)(T), paclitaxel (P), carboplatin (C) and gemcitabine (G) in patientswith advanced urothelial cancer. Proc Am Soc Clin Oncol 2002; 21:800a.50 Al-Sukhun S, Hussain M. Current understanding of the biology ofadvanced bladder cancer. Cancer 2003; 97 (8 suppl): 2064–75.51 Hussain SA, Ganesan R, Hiller L, et al. Pro-apoptotic genes BAX andCD40L are predictors of survival in transitional cell carcinoma of thebladder. Br J Cancer 2003; 88: 586–92.52 Stein JP, Ginsberg DA, Grossfield GD, et al . Effect of p21WAF1/CIP1expression on tumour progression in bladder cancer. J Natl CancerInst 1998; 90: 1072–79.53 Hussain SA, Ganesan R, Hiller L, et al. BCL2 expression predictssurvival in patients receiving synchronous chemoradiotherapy inadvanced transitional cell carcinoma of the bladder. Oncol Rep 2003;10: 571–76.54 Cooke PW, James ND, Ganesan R, et al. Bcl-2 expression identifiespatients with advanced bladder cancer treated by radiotherapy whobenefit from neoadjuvant chemotherapy. BJU Int 2000; 85: 829–35.55 Hussain SA, James ND. Organ preservation strategies in bladdercancer. Expert Rev Anticancer Ther 2002; 2: 641–51.Advances in researchBy use of an immunoperoxidase-based staining assay weinvestigated the presence of CD1a—a T-cell antigen-presentation protein—in 113 oesophageal biopsy samplestaken from patients with Barrett’s metaplasia. 84 of thepatients had undergone biopsy once before and had beengiven a histological classification of either gastric or intestinaltype metaplasia. The remaining 29 patients had undergonebiopsy more than once; histological assessment confirmeddiagnosis in 16 of these, but the metaplasia of 13 patients hadevolved to dysplasia and neoplasia over time. Biopsy samplestaken from 63 (75%) of the once-only biospy group werepositive for CD1a (41/54 patients with gastric type disease,figure a; 22/30 patients with intestinal type disease, figure b)although mucosae from normal stomach and colon tissuewas negative for CD1a in both groups (figure c and figure d,respectively). In the multiple-biopsy group, 15/16 patientswho had had their diagnosis confirmed were positive forCD1a (data not shown), wheras only 1/13 with dysplasic orneoplasic tissue were positive (figure e, dysplastic sample andfigure f, Barrett’s adenocarcinoma). We are unable to explain why CD1a is positive in Barret’smetaplasia and not in normal epithelium, but the presence ofthis marker in neoplastic tissue may, if confirmed byprospective studies, become a useful diagnostic andprognostic tool indicating a favourable outcome in diseaseprogression.CD1a: a novel biomarker for Barrett’s metaplasia?Francesco Cappello, Francesca Rappa, Fabio Bucchieri, and Giovanni ZummoCorrespondence: Dr Francesco Cappello, via alla Falconara 120, 90136 Palermo, Italy. Tel/Fax: + 39 091 6553518. Email: francapp@hotmail.com

CD1a: a novel biomarker for Barrett's metaplasia?

https://iris.unipa.it/retrieve/handle/10447/191018/316183/Cappello%20F%20lancet%20oncology%202003.pdf

CD1a: a novel biomarker for Barrett's metaplasia?

Abstract

Similar works

Full text

Available Versions

Archivio istituzionale della ricerca - Università di Palermo